Y-mAbs Therapeutics Q3 EPS $(0.18) Beats $(0.19) Estimate, Sales $19.95M Miss $20.93M Estimate
Portfolio Pulse from Benzinga Newsdesk
Y-mAbs Therapeutics (NASDAQ:YMAB) reported Q3 earnings with an EPS of $(0.18), slightly better than the $(0.19) estimate, marking a 71.43% improvement from last year. However, sales of $19.95M fell short of the $20.93M estimate, despite being 59.16% higher than the previous year.
November 13, 2023 | 10:34 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Y-mAbs Therapeutics reported better-than-expected Q3 EPS but missed sales estimates, showing significant year-over-year growth.
The mixed results with an EPS beat but a slight miss on revenue projections could lead to a neutral short-term impact on YMAB's stock price. The significant year-over-year growth in both EPS and sales may be viewed positively, but the sales miss could temper investor enthusiasm.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100